Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analyst sentiment is “Moderate Buy”: Six of nine analysts rate Neumora Therapeutics a buy, one a strong buy, one a hold and one a sell. The average 12-month price target is $6.57.
• The stock opened at $0.50, well below its 52-week high of $3.65; its 50-day and 200-day moving averages were $0.69 and $1.74, respectively.
• Neumora reported quarterly EPS of -$0.23, slightly better than the consensus estimate of -$0.24. Insiders sold about 454,000 shares over the past three months.

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.57.

A number of analysts have recently issued reports on NMRA shares. Wall Street Zen upgraded Neumora Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday. HC Wainwright restated a "buy" rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Weiss Ratings upgraded shares of Neumora Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, September 25th. Finally, Royal Bank Of Canada lowered their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th.

Insider Buying and Selling

In other news, insider Daljit Singh Aurora sold 91,690 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.50, for a total value of $137,535.00. Following the transaction, the insider owned 48,750 shares of the company's stock, valued at $73,125. This represents a 65.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 453,833 shares of company stock valued at $701,219. 26.94% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $13,246,000. Perceptive Advisors LLC bought a new position in Neumora Therapeutics during the 1st quarter worth approximately $9,953,000. ICONIQ Capital LLC bought a new position in Neumora Therapeutics during the 2nd quarter worth approximately $4,350,000. Siren L.L.C. increased its stake in Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company's stock worth $16,571,000 after purchasing an additional 2,209,039 shares during the period. Finally, Johnson & Johnson purchased a new position in Neumora Therapeutics in the 2nd quarter worth approximately $3,144,057. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $0.50 on Friday. The firm has a market capitalization of $94.57 million, a price-to-earnings ratio of -0.41 and a beta of 3.12. Neumora Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.65. The stock has a fifty day moving average of $0.69 and a 200 day moving average of $1.74. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, research analysts expect that Neumora Therapeutics will post -0.84 EPS for the current fiscal year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora's pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.